---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000080"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:35:53.189471+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Caribou Q3 net loss $34.7M vs $10.0M YoY; cash $281M funds into H2 2026

## Summary
- Revenue $2.0M, down from $23.7M due to AbbVie termination; R&D expense $30.4M.
- Cash & equivalents $281M as of Sept 30, 2024, down from $372.4M at Dec 31, 2023.
- CB-010 lupus GALLOP Phase 1 trial initiation expected by year-end 2024; Fast Track granted.
- CB-011 CaMMouflage dose escalation data for r/r MM expected H1 2025; no DLTs observed.
- Tina Albertson, MD/PhD, appointed CMO in August 2024; led BREYANZI development.

## SEC filing metadata
- accession: 0001619856-24-000080
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000080/0001619856-24-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000080/crbu-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000080
- JSON: https://secwatch.observer/filing/0001619856-24-000080.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.